JP2023113641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023113641A5 JP2023113641A5 JP2023077454A JP2023077454A JP2023113641A5 JP 2023113641 A5 JP2023113641 A5 JP 2023113641A5 JP 2023077454 A JP2023077454 A JP 2023077454A JP 2023077454 A JP2023077454 A JP 2023077454A JP 2023113641 A5 JP2023113641 A5 JP 2023113641A5
- Authority
- JP
- Japan
- Prior art keywords
- methods
- new products
- manufacturing methods
- manufacturing
- methods substantially
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564095P | 2017-09-27 | 2017-09-27 | |
| US62/564,095 | 2017-09-27 | ||
| US201762574657P | 2017-10-19 | 2017-10-19 | |
| US62/574,657 | 2017-10-19 | ||
| US201762579682P | 2017-10-31 | 2017-10-31 | |
| US62/579,682 | 2017-10-31 | ||
| US201862632812P | 2018-02-20 | 2018-02-20 | |
| US62/632,812 | 2018-02-20 | ||
| JP2020517843A JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
| PCT/US2018/052855 WO2019067540A1 (en) | 2017-09-27 | 2018-09-26 | TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517843A Division JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023113641A JP2023113641A (ja) | 2023-08-16 |
| JP2023113641A5 true JP2023113641A5 (https=) | 2025-05-15 |
Family
ID=65903176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517843A Active JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
| JP2023077454A Pending JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517843A Active JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200277364A1 (https=) |
| EP (1) | EP3687464A4 (https=) |
| JP (2) | JP7685833B2 (https=) |
| KR (2) | KR20200060456A (https=) |
| AU (2) | AU2018342094B2 (https=) |
| CA (1) | CA3076905A1 (https=) |
| IL (1) | IL273403A (https=) |
| SG (1) | SG11202002396TA (https=) |
| WO (1) | WO2019067540A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373894B (es) | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| SG11201808426XA (en) | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| US20220133908A1 (en) * | 2019-02-08 | 2022-05-05 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
| WO2020206098A1 (en) * | 2019-04-03 | 2020-10-08 | Regenxbio Inc. | Gene therapy for eye pathologies |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| CN114502197A (zh) * | 2019-08-26 | 2022-05-13 | 再生生物股份有限公司 | 用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变 |
| WO2021071835A1 (en) | 2019-10-07 | 2021-04-15 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021188803A1 (en) * | 2020-03-19 | 2021-09-23 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
| JP2023535632A (ja) | 2020-07-27 | 2023-08-18 | アンジャリウム バイオサイエンシズ エージー | Ｄｎａ分子の組成物、その作製方法、及びその使用方法 |
| CA3198368A1 (en) * | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| MX2024003320A (es) * | 2021-09-18 | 2024-06-28 | Skyline Therapeutics Ltd | Virus adenoasociado para terapia génica de degeneración macular húmeda asociada con la edad. |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US20070202186A1 (en) * | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| SG176202A1 (en) * | 2009-05-28 | 2011-12-29 | Glaxo Group Ltd | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye. |
| EP2443150B1 (en) * | 2009-06-17 | 2015-01-21 | AbbVie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| EP2559443A1 (en) * | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| CA2922483A1 (en) * | 2013-09-11 | 2015-03-19 | Neurotech Usa, Inc. | Encapsulated cell therapy cartridge |
| US10064752B2 (en) * | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| CA3010862A1 (en) * | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| KR20240005973A (ko) * | 2016-04-15 | 2024-01-12 | 리젠엑스바이오 인크. | 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료 |
| SG11201808426XA (en) * | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| US12558434B2 (en) * | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| WO2021188803A1 (en) * | 2020-03-19 | 2021-09-23 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
-
2018
- 2018-09-26 EP EP18862872.1A patent/EP3687464A4/en active Pending
- 2018-09-26 CA CA3076905A patent/CA3076905A1/en active Pending
- 2018-09-26 WO PCT/US2018/052855 patent/WO2019067540A1/en not_active Ceased
- 2018-09-26 KR KR1020207011989A patent/KR20200060456A/ko not_active Ceased
- 2018-09-26 KR KR1020257008245A patent/KR20250040754A/ko active Pending
- 2018-09-26 US US16/645,877 patent/US20200277364A1/en not_active Abandoned
- 2018-09-26 SG SG11202002396TA patent/SG11202002396TA/en unknown
- 2018-09-26 JP JP2020517843A patent/JP7685833B2/ja active Active
- 2018-09-26 AU AU2018342094A patent/AU2018342094B2/en active Active
-
2020
- 2020-03-18 IL IL273403A patent/IL273403A/en unknown
-
2023
- 2023-05-09 JP JP2023077454A patent/JP2023113641A/ja active Pending
- 2023-07-27 US US18/360,073 patent/US20240254214A1/en not_active Abandoned
-
2025
- 2025-02-26 US US19/064,049 patent/US20250320287A1/en active Pending
- 2025-05-02 AU AU2025203154A patent/AU2025203154A1/en active Pending